Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 7/20 | 0.57 |
| ▸ | NOS1 | P29475 | 6/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | NOS3 | P29474 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | GSR | P00390 | 1/20 | 0.52 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.51 |
| ▸ | ARG2 | P78540 | 4/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ARG1 | P05089 | 3/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28360554 | 1.00 | NOS2 (0.57) | NOS2NOS1BLMNOS3CYP1A2 | |
| SCHEMBL14031296 | 0.98 | NOS2 (0.56) | NOS2NOS1BLMNOS3CYP1A2 | |
| SCHEMBL14439654 | 0.98 | NOS2 (0.56) | NOS2NOS1BLMNOS3CYP1A2 | |
| SCHEMBL29588594 | 0.98 | NOS2 (0.56) | NOS2NOS1BLMNOS3CYP1A2 | |
| SCHEMBL24767454 | 0.96 | NOS2 (0.57) | NOS2NOS1BLMNOS3CYP1A2 | |
| SCHEMBL16892793 | 0.96 | NOS2 (0.57) | NOS2NOS1BLMNOS3CYP1A2 | |
| SCHEMBL16155902 | 0.96 | NOS2 (0.57) | NOS2NOS1BLMNOS3CYP1A2 | |
| SCHEMBL23586514 | 0.96 | NOS2 (0.57) | NOS2NOS1BLMNOS3CYP1A2 | |
| SCHEMBL16892792 | 0.96 | NOS2 (0.57) | NOS2NOS1BLMNOS3CYP1A2 | |
| Hydrochloric Acid SCHEMBL28356364 | 0.94 | NOS2 (0.56) | NOS2NOS1BLMNOS3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116920-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE | PEPTIDREAM INC. (JP) | 2026-04-30 | — | — | US | disclosed |
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4667483-A1 | HUMAN TRANSFERRIN RECEPTOR-BINDING PEPTIDE | JCR Pharmaceuticals Co., Ltd. (JP) | 2025-12-24 | — | — | EP | disclosed |
| EP-4608455-A1 | SELF-ASSEMBLING NANOPARTICLES | Barinthus Biotherapeutics North America, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4608437-A2 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | Barinthus Biotherapeutics North America, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250242015-A1 | SELF-ASSEMBLING NANOPARTICLES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2025-07-31 | — | — | US | disclosed |
| WO-2025100520-A1 | PEPTIDE, PEPTIDE COMPLEX, PHARMACEUTICAL COMPOSITION, COMPOSITION FOR CELL CULTURE, AND COMPOSITION FOR MEDICAL USE, DIAGNOSTIC USE, OR RESEARCH USE | ペプチドリーム株式会社 | 2025-05-15 | — | — | WO | disclosed |
| US-20250127887-A1 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025061971-A1 | FUNCTIONALIZED PEPTIDES FOR IN-VIVO ADDRESSING OF PD-L1 EXPRESSION | TRIMT GMBH (DE) | 2025-03-27 | — | — | WO | disclosed |
| US-20240390508-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE-DRUG CONJUGATE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| WO-2022177993-A1 | SELF-ASSEMBLING NANOPARTICLES BASED ON AMPHIPHILIC PEPTIDES | VACCITECH NORTH AMERICA, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| EP-4021470-A2 | METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST NEOANTIGENS | TURNSTONE BIOLOGICS CORP. (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20210393523-A1 | AROMATIC RING SUBSTITUTED AMPHIPHILIC POLYMERS AS DRUG DELIVERY SYSTEMS | Avldea Technologies, Inc. (US) | 2021-12-23 | — | — | US | disclosed |
| US-11124818-B2 | Method for modifying microcystins and nodularins | CYANO BIOTECH GMBH (DE) | 2021-09-21 | — | — | US | disclosed |
| EP-3860646-A1 | AROMATIC RING SUBSTITUTED AMPHIPHILIC POLYMERS AS DRUG DELIVERY SYSTEMS | Avidea Technologies, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2021041518-A2 | METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST NEOANTIGENS | TURNSTONE BIOLOGICS CORP. (US) | 2021-03-04 | — | — | WO | disclosed |
| US-20200377922-A1 | METHOD FOR MODIFYING MICROCYSTINS AND NODULARINS | CYANO BIOTECH GMBH (DE) | 2020-12-03 | — | — | US | disclosed |
| WO-2020072681-A1 | AROMATIC RING SUBSTITUTED AMPHIPHILIC POLYMERS AS DRUG DELIVERY SYSTEMS | AVIDEA TECHNOLOGIES, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| US-20200087348-A1 | MODIFIED MICROCYSTINS AND NODULARINS | CYANO BIOTECH GMBH (DE) | 2020-03-19 | — | — | US | disclosed |
| CN-110730787-A | Modified microcystins and nodulotoxins | 赛安诺生物技术有限责任公司 | 2020-01-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127887-A1 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides | IAPP, BRCA1, ANXA11 | GLA 1902/4885NOS2 3662/4885NOS1 3411/4885 |
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | IL2, IFNG, ICOS | GLA 4027/4885NOS2 263/4885NOS1 412/4885 |
| US-20260116920-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE | MET, TFRC, SLC7A1 | GLA 4597/4885NOS2 2123/4885NOS1 2151/4885 |
| US-20250242015-A1 | SELF-ASSEMBLING NANOPARTICLES | UBE2B, CD4, HRH1 | GLA 2451/4885NOS2 2767/4885NOS1 2292/4885 |
| US-20240390508-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE-DRUG CONJUGATE | MUSK, TFRC, SLC7A1 | GLA 4357/4885NOS2 2929/4885NOS1 2235/4885 |
| US-11124818-B2 | Method for modifying microcystins and nodularins | NRDC, NGLY1, NLN | GLA 3252/4885NOS2 265/4885NOS1 145/4885 |
| US-20200377922-A1 | METHOD FOR MODIFYING MICROCYSTINS AND NODULARINS | NRDC, NGLY1, NLN | GLA 3259/4885NOS2 242/4885NOS1 126/4885 |
| US-20210393523-A1 | AROMATIC RING SUBSTITUTED AMPHIPHILIC POLYMERS AS DRUG DELIVERY SYSTEMS | SBDS, APOB, ABCD3 | GLA 3851/4885NOS2 4505/4885NOS1 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.